Vistagen Therapeutics, Inc. (VTGN)
| Market Cap | 23.64M |
| Revenue (ttm) | 789,000 |
| Net Income (ttm) | -67.05M |
| Shares Out | 39.62M |
| EPS (ttm) | -1.89 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 504,946 |
| Open | 0.580 |
| Previous Close | 0.571 |
| Day's Range | 0.566 - 0.610 |
| 52-Week Range | 0.430 - 5.140 |
| Beta | 0.33 |
| Analysts | Hold |
| Price Target | 0.90 (+50.86%) |
| Earnings Date | Jun 16, 2026 |
About VTGN
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company’s product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also devel... [Read more]
Financial Performance
In fiscal year 2025, Vistagen Therapeutics's revenue was $486,000, a decrease of -54.32% compared to the previous year's $1.06 million. Losses were -$51.42 million, 75.1% more than in 2024.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for VTGN stock is "Hold." The 12-month stock price target is $0.9, which is an increase of 50.86% from the latest price.
News
Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum
Fasedienol is advancing in phase III for social anxiety disorder, with PALISADE-4 results expected in the first half of the year. AI-driven analytics and operational improvements are being applied to enhance trial outcomes, while a robust data package and additional pipeline assets support future regulatory and clinical milestones.
Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Vistagen (VTGN) To Contact Him Directly To Discuss Their Options
Vistagen to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The conference highlighted a pipeline of non-systemic, intranasal drug candidates targeting large unmet needs in neuropsychiatry and women's health. Lead asset Fasedienol showed positive phase III results in social anxiety disorder, with further pivotal data expected in H1 2026. AI-driven trial optimization and multiple regulatory strategies are being pursued.
Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Earnings Call Transcript: Q3 2026
Completed PALISADE-3 and advanced PALISADE-4 with operational refinements and AI-driven analytics. Cash position at $61.8M as of December 31, 2025, with ongoing cash preservation. IND for rafisolone planned for H1 2026.
Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired secur...
VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel
SAN DIEGO, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Vistagen Therapeutics,...
Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered In Vistagen To Contact Him Directly To Discuss Their Options If you purchased or acquired secur...
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP: Do you, or did you, own shares of Vistagen Therapeutics, Inc. (NASDAQ: VTGN)? Did you purchase your shares between April 1, 2024 and...
VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
NEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquir...
Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study
Vistagen Inc. (NASDAQ: VTGN) stock is plunging on Wednesday, with a session volume of 20.91 million compared to the average volume of 711,000, as per data from Benzinga Pro.
Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Appoints Nick Tressler as Chief Financial Officer
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Earnings Call Transcript: Q2 2026
Major progress in phase III trials for fasedienol in social anxiety disorder, with top-line results from PALISADE 3 expected by year-end and strong financial position to support ongoing programs. Pipeline expansion and new board leadership position the company for transformative growth.
Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference
A novel neurocircuitry-targeted drug for social anxiety is advancing through late-stage trials, with PALISADE-3 data expected by year-end. Enhanced trial design, robust safety data, and regulatory alignment support its differentiated profile and potential for broad impact, especially among younger patients.
Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen to Participate in Stifel Healthcare Conference 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...
Vistagen Appoints Paul Edick to its Board of Directors
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commerci...